GlassScriptPhysician profile
Tamara A Stout
NPI 1275568727
$4,274.90
in general payments reported to CMS, 2019-2025
25 companies · $858 in 2025
The $858 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $721 · 2021: $881 · 2022: $482 · 2023: $264 · 2024: $611 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,733.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $904.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $798.69 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $631.58 | 2020-2025 | Ozempic, Rybelsus |
| Eisai INC. | $201.02 | 2019-2021 | |
| Abbvie INC. | $193.89 | 2021-2025 | |
| Stryker Corporation | $165.78 | 2025 | Mako |
| Bayer Healthcare Pharmaceuticals INC. | $152.78 | 2025 | |
| Exact Sciences Corporation | $150.01 | 2023-2024 | Cologuard Collection Kit |
| Corium, LLC | $142.16 | 2022 | |
| Allergan, INC. | $138.72 | 2019-2020 | |
| Amgen INC. | $119.79 | 2020-2023 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.13 | 2019 | |
| Sanofi Pasteur INC. | $99.12 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $68.03 | 2020 | |
| Currax Pharmaceuticals LLC | $61.40 | 2019-2024 | Contrave, Onzetra Xsail |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $54.43 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.17 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.44 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $47.85 | 2020-2021 | |
| Pfizer INC. | $43.02 | 2024-2025 | |
| Glaxosmithkline, LLC. | $22.27 | 2023 | Shingrix, Arexvy |
| Seqirus USA INC | $20.46 | 2019 | |
| Alkermes, INC. | $18.88 | 2023 | Vivitrol |
| Genentech USA, INC. | $18.30 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Stout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.